What is the typical dose of Desmopressin?

Typical research doses are 10-20 mcg, administered 1-2x daily. Commonly timed: Evening for nocturnal enuresis; morning and evening for diabetes insipidus management. These are research figures only — not clinical recommendations.

What are the known side effects of Desmopressin?

Side effects reported in research include: Hyponatremia (low serum sodium) (uncommon, serious); Headache (common, mild); Nausea and vomiting (uncommon, mild); Abdominal cramping (uncommon, mild); Facial flushing (rare, mild); Local injection site reactions (uncommon, mild); Allergic reaction (rare, serious); Water intoxication (rare, serious); Thrombosis (rare with high doses) (rare, serious). Always consult a qualified professional before use.

How is Desmopressin administered?

Desmopressin is typically administered via Subcutaneous or Intranasal or Oral.

Can Desmopressin be injected?

In the research literature, Desmopressin is described with subcutaneous or intranasal or oral administration. This is research information only, not medical advice.

Specialized Peptides / Subcutaneous / Intranasal

Desmopressin

Q: What is Desmopressin used for in research?

Research on Desmopressin has focused on: Reduces nocturnal polyuria and nighttime urination; Manages central diabetes insipidus symptoms; Improves hemostasis in von Willebrand disease; Enhances aquaporin-2 water channel expression; Reduces serum osmolality in polydipsia.

Also known as DDAVP, 1-deamino-8-D-arginine vasopressin, Minirin, Stimate

A synthetic vasopressin analog that regulates water reabsorption and is used clinically for diabetes insipidus, nocturnal enuresis, and hemophilia management.

What is Desmopressin used for? Research has focused on reduces nocturnal polyuria and nighttime urination; manages central diabetes insipidus symptoms; improves hemostasis in von willebrand disease.

Compare with other peptides studied formuscle growth

Desmopressin injection at a glance

Figures from the published research literature. Research use only.

Dose range: 10-20 mcg
Route: Subcutaneous, Intranasal, Oral

How often, when, and the dosing notes are in the dosing reference further down.

Work out your units in the free calculator

Beginner basics

Plain-English guide to Desmopressin

What it does: Desmopressin helps your body hold onto water by signaling kidneys to reabsorb it instead of releasing it as urine. Researchers use it to study water balance in the body and to manage excessive nighttime urination.
Typical dose: 10-20 micrograms (mcg) once or twice daily, injected under the skin, though intranasal and oral forms exist with different dosing.
When to inject: Evening is typical for nighttime urination issues; morning and evening for managing water balance problems. Start with the lower dose and adjust based on response.
Storage: Keep the dry powder at room temperature away from light and moisture. Once mixed with liquid, store in the refrigerator and use within the timeframe specified by your supplier.
Beginner tip: Start at the low end of the dose range and increase slowly while monitoring how your body responds-this peptide affects fluid balance, so gradual adjustment is safer than jumping to higher doses.

Research status

FDA-approved

For research purposes only. Not approved for human use. Not medical advice.

Research areas

Reduces nocturnal polyuria and nighttime urination
Manages central diabetes insipidus symptoms
Improves hemostasis in von Willebrand disease
Enhances aquaporin-2 water channel expression
Reduces serum osmolality in polydipsia

Side effects

Effect	How often	Severity
Hyponatremia (low serum sodium)Occurs when desmopressin-induced water reabsorption exceeds water intake, diluting serum sodium. Symptoms include headache, nausea, confusion, lethargy, seizures, and coma. Risk increases with excessive fluid intake, renal impairment, or SIADH. Requires immediate medical evaluation and serum sodium measurement. Fluid restriction is the primary management strategy.	Uncommon	Serious
HeadacheOften mild and self-resolving. May be related to hyponatremia or local injection site effects. Monitor serum sodium if headaches persist or worsen.	Common	Mild
Nausea and vomitingUsually mild and transient. May occur within 1-2 hours of injection. Can be a sign of hyponatremia; monitor serum sodium if symptoms persist.	Uncommon	Mild
Abdominal crampingMild gastrointestinal discomfort may occur, particularly with higher doses. Typically resolves within a few hours.	Uncommon	Mild
Facial flushingTransient facial flushing or warmth may occur due to mild vasodilation from V1 receptor activation. Self-resolving.	Rare	Mild
Local injection site reactionsMild erythema, swelling, or discomfort at the injection site. Prevented by proper site rotation and injection technique. Apply ice if needed.	Uncommon	Mild
Allergic reactionRare but possible; includes urticaria, angioedema, or anaphylaxis. Seek immediate medical attention if difficulty breathing, throat swelling, or severe rash occurs.	Rare	Serious
Water intoxicationSevere hyponatremia with cerebral edema, seizures, and altered consciousness. Occurs with excessive desmopressin dosing and high fluid intake. Requires emergency medical intervention and fluid restriction.	Rare	Serious
Thrombosis (rare with high doses)Very rare; reported with high-dose desmopressin in patients with thrombotic risk factors. Monitor for signs of deep vein thrombosis or pulmonary embolism.	Rare	Serious

Dosing reference

Dose scale from the research

Starting: 10 mcg
Typical: 15 mcg
Upper end: 20 mcg

Desmopressin dosing reference
Parameter	Value
Dose range	10-20 mcg
Frequency, timing and route are for members Sign up free Log in

Checked October 2026

Research disclaimer. Figures are drawn from published research literature and community logs. They are not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution guide

Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2-8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration

Worked example

With 5 mg in the vial, the water you add changes the draw. Mixed with 1 mL that is 5,000 mcg per mL, so on a U-100 syringe 10 mcg is 0.2 units and 20 mcg is 0.4 units. Mixed with 2 mL it is 2,500 mcg per mL, so 10 mcg is 0.4 units and 20 mcg is 0.8 units.

Work out your exact dose in the free peptide calculator

Molecular and pharmacological data

Molecular weight	1069.2
Half-life	2.5 hours (subcutaneous); 1.5-2.5 hours (intranasal)
Sequence	Members only

Desmopressin is a synthetic analog of vasopressin (antidiuretic hormone) that selectively activates V2 receptors on the principal cells of the kidney's collecting duct. This activation increases aquaporin-2 water channel expression and insertion into the apical membrane, enhancing water reabsorption and reducing urine output. It also has weak V1 receptor activity, which contributes to hemostatic effects by promoting von Willebrand factor and factor VIII release from endothelial cells.

Pathways and mechanism detail are for members

Keep a log of your Desmopressin research

Free account. No credit card required.

Start free Goal finder Interaction checker

Recent research

All results on PubMed

Source: PubMed / NCBI. Updated daily. Articles are listed for research reference only.

Research citations

5 sources

Robson WL, Leung AK, Kaplan BS. (1997). Desmopressin therapy for nocturnal enuresis. Pediatric Nephrology. PMID: 9153674. Systematic review demonstrating efficacy of desmopressin in reducing nighttime voiding episodes in children.
Coad JE, Al-Rasadi K, Reusch JE. (2002). Desmopressin in the management of diabetes insipidus. Endocrine Reviews. DOI: 10.1210/er.2002-0003. Comprehensive clinical pharmacology of desmopressin for central diabetes insipidus.
Franchini M, Lippi G. (2011). Desmopressin: a new use for an old drug. Thrombosis and Haemostasis. PMID: 21901243. Evidence for desmopressin in hemostatic disorders including von Willebrand disease.
Bichet DG. (2008). Vasopressin and desmopressin in central diabetes insipidus: maximal efficacy and safety by appropriate dosing. American Journal of Nephrology. PMID: 18701822. Dosing strategies and safety monitoring for desmopressin therapy.
Thibonnier M, Shoham M. (1991). Molecular mechanisms of vasopressin action. Advances in Experimental Medicine and Biology. PMID: 1928806. Mechanism of V2 receptor activation and aquaporin-2 upregulation.

All Specialized Peptides peptides

Browse the research library

147 peptide profiles and 59 blend profiles with mechanism summaries, dosing data and reconstitution guides.

View all peptides

Stay updated on Desmopressin research

A weekly digest of new peptide research, stack guides and site updates.

Research use only. All content on this page is provided for informational and educational purposes related to scientific research. Desmopressin is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.